Latest Insider Transactions at Axonics, Inc. (AXNX)
This section provides a real-time view of insider transactions for Axonics, Inc. (AXNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Axonics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Axonics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 15
2024
|
Esteban Lopez |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,600
-100.0%
|
$468,600
$71.0 P/Share
|
|
Nov 15
2024
|
Robert Mc Namara |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,861
-100.0%
|
$1,055,131
$71.0 P/Share
|
|
Nov 15
2024
|
Karen Noblett Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
34,428
-100.0%
|
$2,444,388
$71.0 P/Share
|
|
Nov 15
2024
|
Rinda Sama Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
608
-100.0%
|
$43,168
$71.0 P/Share
|
|
Nov 15
2024
|
Rinda Sama Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
83,854
-100.0%
|
$5,953,634
$71.0 P/Share
|
|
Nov 15
2024
|
Nancy Lynn Md Snyderman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,944
-100.0%
|
$1,061,024
$71.0 P/Share
|
|
Nov 15
2024
|
John Woock EVP, Chief Mktg/Strtgy Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
77,403
-100.0%
|
$5,495,613
$71.0 P/Share
|
|
Nov 15
2024
|
Jane E Kiernan |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,861
-100.0%
|
$1,410,131
$71.0 P/Share
|
|
Nov 15
2024
|
Michael H Carrel |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,861
-100.0%
|
$1,268,131
$71.0 P/Share
|
|
Nov 15
2024
|
Raymond W Cohen Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
292,731
-100.0%
|
$20,783,901
$71.0 P/Share
|
|
Nov 15
2024
|
David M Demski |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,542
-100.0%
|
$677,482
$71.0 P/Share
|
|
Nov 15
2024
|
Alfred J Ford Jr Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,450
-100.0%
|
$3,084,950
$71.0 P/Share
|
|
Nov 15
2024
|
Kari Leigh Keese Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
40,362
-100.0%
|
$2,865,702
$71.0 P/Share
|
|
Nov 07
2024
|
Nancy Lynn Md Snyderman |
SELL
Bona fide gift
|
Direct |
5,000
-25.07%
|
-
|
|
Oct 02
2024
|
Kari Leigh Keese Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,961
-3.44%
|
$204,309
$69.41 P/Share
|
|
Jul 24
2024
|
Raymond W Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
103,896
+15.89%
|
$2,077,920
$20.01 P/Share
|
|
Jan 31
2024
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,288
-24.69%
|
$756,296
$67.74 P/Share
|
|
Jan 31
2024
|
Karen Noblett Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+37.56%
|
-
|
|
Jan 31
2024
|
Rinda Sama Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+25.03%
|
-
|
|
Jan 31
2024
|
Raymond W Cohen Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
35,161
-15.7%
|
$2,355,787
$67.74 P/Share
|
|
Jan 31
2024
|
Raymond W Cohen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
63,400
+22.06%
|
-
|
|
Jan 31
2024
|
Kari Leigh Keese Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,489
-7.45%
|
$233,763
$67.74 P/Share
|
|
Jan 31
2024
|
Kari Leigh Keese Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,167
+11.64%
|
-
|
|
Jan 31
2024
|
Alfred J Ford Jr Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
16,615
-27.66%
|
$1,113,205
$67.74 P/Share
|
|
Jan 31
2024
|
Alfred J Ford Jr Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,500
+29.8%
|
-
|
|
Jan 31
2024
|
John Woock EVP, Chief Mktg/Strtgy Officer |
SELL
Open market or private sale
|
Direct |
15,899
-17.04%
|
$1,065,233
$67.74 P/Share
|
|
Jan 31
2024
|
John Woock EVP, Chief Mktg/Strtgy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+23.08%
|
-
|
|
Jan 08
2024
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,999
-46.76%
|
$1,103,931
$69.0 P/Share
|
|
Dec 28
2023
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,051
-17.09%
|
$444,213
$63.28 P/Share
|
|
Dec 26
2023
|
Karen Noblett Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
949
-2.25%
|
$59,787
$63.0 P/Share
|
|
Sep 29
2023
|
Danny L. Dearen President & CFO |
SELL
Open market or private sale
|
Direct |
7,675
-24.4%
|
$429,800
$56.87 P/Share
|
|
Sep 29
2023
|
Danny L. Dearen President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
11,250
+26.35%
|
-
|
|
Aug 15
2023
|
Alfred J Ford Jr Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
14,769
-29.94%
|
$915,678
$62.34 P/Share
|
|
Aug 08
2023
|
Michael H Carrel |
SELL
Bona fide gift
|
Direct |
500
-2.72%
|
-
|
|
Jul 28
2023
|
Alfred J Ford Jr Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,500
-2.95%
|
$93,000
$62.01 P/Share
|
|
Jun 26
2023
|
Robert Mc Namara |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+16.8%
|
-
|
|
Jun 26
2023
|
Michael H Carrel |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+14.04%
|
-
|
|
Jun 26
2023
|
Nancy Lynn Md Snyderman |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+13.08%
|
-
|
|
Jun 26
2023
|
Jane E Kiernan |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+13.12%
|
-
|
|
Jun 26
2023
|
David M Demski |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+23.92%
|
-
|
|
Jun 26
2023
|
Esteban Lopez |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+31.25%
|
-
|
|
May 26
2023
|
Danny L. Dearen President & CFO |
SELL
Open market or private sale
|
Direct |
7,999
-23.96%
|
$391,951
$49.79 P/Share
|
|
Apr 21
2023
|
Danny L. Dearen President & CFO |
SELL
Open market or private sale
|
Direct |
20,000
-31.88%
|
$1,200,000
$60.22 P/Share
|
|
Apr 21
2023
|
Danny L. Dearen President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,208
+26.2%
|
$184,912
$14.19 P/Share
|
|
Apr 20
2023
|
Danny L. Dearen President & CFO |
SELL
Open market or private sale
|
Direct |
2,001
-7.7%
|
$120,060
$60.01 P/Share
|
|
Apr 20
2023
|
Danny L. Dearen President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,001
+7.15%
|
$28,014
$14.19 P/Share
|
|
Mar 31
2023
|
Danny L. Dearen President & CFO |
SELL
Open market or private sale
|
Direct |
15,000
-21.5%
|
$825,000
$55.26 P/Share
|
|
Mar 31
2023
|
Danny L. Dearen President & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+12.63%
|
$195,000
$13.88 P/Share
|
|
Feb 21
2023
|
Rinda Sama Chief Operating Officer |
SELL
Open market or private sale
|
Indirect |
3,392
-84.8%
|
$189,952
$56.53 P/Share
|
|
Feb 21
2023
|
Rinda Sama Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
19,929
-13.81%
|
$1,116,024
$56.43 P/Share
|